Lascelles, K;
Afridi, S;
Siddiqui, A;
Hemingway, C;
Ferner, R;
Ganesan, V;
(2018)
Cerebral vasculopathy in childhood neurofibromatosis type 2: cause for concern?
Developmental Medicine and Child Neurology
, 60
(12)
pp. 1285-1288.
10.1111/dmcn.13920.
Preview |
Text
Ganesan_Lascelles NF2 final draft CASE_SF_AB KL.pdf - Accepted Version Download (345kB) | Preview |
Abstract
Unlike adult neurofibromatosis type 2 (NF2), which presents with symptoms related to bilateral vestibular schwannomas, children with NF2 most frequently present with ocular, dermatological, and neurological symptoms. Arteriopathy, a well-established feature in neurofibromatosis type 1, is not a widely recognized feature of NF2. Here we report three children with NF2 with cerebral arteriopathy and/or arterial ischaemic stroke. Bevacizumab, a vascular endothethial growth factor inhibitor, is an established treatment for rapidly growing vestibular schwannomas; however, it carries a risk of both ischaemic and haemorrhagic stroke. Thus, the role of screening and risk to benefit ratio of bevacizumab in NF2 merit further consideration. WHAT THIS PAPER ADDS: Children with neurofibromatosis type 2 (NF2) may be at increased risk of cerebral vasculopathy and arterial ischaemic stroke. Targeted magnetic resonance angiography should be performed in children with NF2 who are being considered for bevacizumab therapy.
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
